Parkinson disease and growth factors — is GDNF good enough?

Agnete Kirkeby*, Roger A. Barker

*Corresponding author af dette arbejde
12 Citationer (Scopus)

Abstract

Previous open-label trials testing glial cell line-derived neurotrophic factor (GDNF) family ligands in Parkinson disease have shown promising clinical effects. However, in placebo-controlled trials, the treatments have failed. A new randomized placebo-controlled trial of intraputamenal delivery of GDNF designed to resolve this conundrum has again failed to do just that.

OriginalsprogEngelsk
TidsskriftNature Reviews Neurology
Vol/bind15
Udgave nummer6
Sider (fra-til)312-314
Antal sider3
ISSN1759-4758
DOI
StatusUdgivet - 1 jun. 2019

Fingeraftryk

Dyk ned i forskningsemnerne om 'Parkinson disease and growth factors — is GDNF good enough?'. Sammen danner de et unikt fingeraftryk.

Citationsformater